Acute Lymphoblastic Leukemia Clinical Trials in Madrid

13 recruitingMadrid, Spain

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled86 locationsNCT04521231
Recruiting
Phase 1

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
Autolus Limited30 enrolled8 locationsNCT06173518
Recruiting
Phase 3

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 2

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Acute Lymphoblastic Leukemia
Pfizer100 enrolled74 locationsNCT05748171
Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled79 locationsNCT06137118
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 3

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology160 enrolled112 locationsNCT05327894
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 1Phase 2

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting
Phase 1Phase 2

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05745714
Recruiting
Phase 1Phase 2

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled36 locationsNCT05658640
Recruiting
Phase 1Phase 2

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Not Applicable

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia
PETHEMA Foundation300 enrolled108 locationsNCT04179929